Our aim was to prospectively assess the prognostic value of beta2- microglobulin (b2-M) in patients with acute pulmonary embolism (PE). We conducted a prospective study of 109 patients admitted in a pulmonary clinic due to acute PE. A panel of inflammatory markers including b2-M white blood cell (WBC) count and C-reactive protein (CRP) was determined for each patient. In this preliminary study, baseline b2-M levels significantly correlated with the impairment of oxygenation and with all the parameters that are used for the early risk stratification of patients. In multivariate analysis, patients’ age and baseline b2-M levels were significantly associated with an increased risk of death.

These findings require further prospective validation.

[download-attachments container="div" style="list" display_icon="1" display_count="1" display__size="0"]

References

1. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov
   14;35(43):3033-69, 3069a-3069k.
2. Sanchez O, Trinquart L, Colombet I, Durieux P, Huisman MV, Chatellier G, Meyer G. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: A systematic review. Eur Heart J 2008;29:1569–1577.
3. Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, BeyerWestendorf J, et al. Fibrinolysis for patients with intermediaterisk pulmonary embolism. N Engl J Med 2014;370(15): 1402–1411.
4. Saghazadeh A, Rezaei N. Inflammation as a cause of venous thromboembolism. Crit Rev Oncol Hematol. 2016 Jan 16. pii: S1040-8428(16)30006-3.
5. Poredos P, Jezovnik MK. The role of inflammation in venous thromboembolism and the link between arterial and venous thrombosis. Int Angiol. 2007 Dec;26(4):306-11. Review.
6. Watts JA, Gellar MA, Obraztsova M, Kline JA, Zagorski J. Role of inflammation in right ventricular damage and repair following experimental pulmonary embolism in rats. Int J Exp Pathol 2008;89:389–399.
7. von Brühl ML, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012;209:819–835.
8. Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis: a systematic review of clinical studies. Thromb Haemost 2005; 94: 362-5.
9. Huang CM, Lin YC, Lin YJ, Chang SL, Lo LW, Hu YF, et al. Risk stratification and clinical outcomes in patients with acute pulmonary embolism. Chen SA. Clin Biochem. 2011Sep;44(13):1110-5.
10. Abul Y, Karakurt S, Ozben B, Toprak A, Celikel T. C-reactive protein in acute pulmonary embolism. J Investig Med. 2011 Jan;59(1):8-14.
11. Uhm JS1, Jung HO, Kim CJ, Kim TH, Youn HJ, Baek SH, et al. Comparison of clinical and imaging characteristics and outcomes between provoked and unprovoked acute pulmonary embolism in Koreans. J Korean Med Sci. 2012 Nov;27(11):1347-53.
12. Sen HS, Abakay O, Tanrikulu AC, Sezgi C, Taylan M, Abakay A, et al. Is a complete blood cell count useful in determining the prognosis of pulmonary embolism? Wien Klin Wochenschr. 2014 Jun;126(11-12):347-54.
13. Hogg K, Hinchliffe E, Haslam S, Sethi B, Carrier M, Lecky F. Thromb Res. 2013 Apr;131(4):e141-6. doi: 10.1016/j.thromres.2013.01.030. Epub 2013 Feb 14.
14. Kawai K, Kawashima S, Miyazaki T, Tajiri E, Mori M, Kitazaki K, et al. Serum beta2-microglobulin concentration as a novel marker to distinguish levels of risk in acute heart failure patients. J Cardiol. 2010 Jan;55(1):99-107.
15. Berggård I, Bearn AG. Isolation and properties of a low molecular weight beta2-microglobulin occurring in human biological fluids. J Biol Chem 1968; 243: 4095.
16. Donadio C, Lucchesi A, Ardini M, Giordani R. Cystatin C, beta 2-microglobulin, and retinol-binding protein as indicators of glomerular filtration rate: comparison with plasma creatinine. J Pharm Biomed Anal 2001;24:835-42.
17. Aksun SA, Ozmen D, Ozmen B, Parildar Z, Mutaf I, Turgan N, et al. Beta2-microglobulin and cystatin C in type 2 diabetes: assessment of diabetic nephropathy. Exp Clin Endocrinol Diabetes 2004;112:195-200.
18. Schardijn GH, Statius van Eps LW. Beta 2-microglobulin: its significance in the evaluation of renal function. Kidney Int 1987;32:635-41.
19. Yoo C, Yoon DH, Suh C. Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor. Blood Res. 2014 Sep;49(3):148-53. doi: 10.5045/br.2014.49.3.148. Epub 2014 Sep 25.
20. Swan FJ, Velasquez WS, Tucker S, Redman JR, Rodriguez MA, McLaughlin P, et al. A new serologic staging system for largecell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol 1989;7:1518-27.
21. Durie BG, Stock-Novack D, Salmon SE, Finley P, Beckord J, Crowley J, Coltman CA. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood 1990;75:823-30.
22. Falus A, Merétey K, Glikmann G, Svehag SE, Fábián F, Böhm U, Bozsöky S. Beta2-microglobulin-containing IgG complexes in sera and synovial fluids of rheumatoid arthritis and systemic lupus erythematosus patients. Scand J Immunol 1981; 13: 25–34.
23. Kaas Ibsen K, Krabbe S, Hesse J. Beta2-microglobulin serum levels in infectious mononucleosis in childhood. Acta Pathol Microbiol Scand (Sect. C) 1981; 89: 205–208.
24. Shinkai S, Chaves PH, Fujiwara Y, Watanabe S, Shibata H, Yoshida H, Suzuki T. Beta2-microglobulin for risk stratification of total mortality in the elderly population: comparison with cystatin C and C-reactive protein. Arch Intern Med 2008;168:200-6.
25. Lippi G, Favaloro EJ, Montagnana M, Franchini M. C-reactive protein and venous thromboembolism: causal or casual association? Clin Chem Lab Med 2010; 48: 1693-701.
26. Möckel M, Muller R, Searle J, Slagman A, De Bruyne B, Serruys P, et al. Usefulness of Beta2-Microglobulin as a Predictor of AllCause and Nonculprit Lesion-Related Cardiovascular Events in Acute Coronary Syndromes (from the PROSPECT Study). Am J Cardiol. 2015 Oct 1;116(7):1034-40.
27. Turner SJ, Ketch TR, Gandhi SK, Sane DC. Routine hematologic clinical tests as prognostic markers in patients with acute coronary syndromes. Am Heart 2008;155:806–816.
28. Fiutowski M, Waszyrowski T, Krzemińska-Pakula M, Kasprzak JD. Pulmonary edema prognostic score predicts in-hospital mortality risk in patients with acute cardiogenic pulmonary edema. Heart Lung 2008;37:46–53.
29. Whiteley W1, Jackson C, Lewis S, Lowe G, Rumley A, Sandercock P, et al. Inflammatory markers and poor outcome after stroke: A prospective cohort study and systematic review of interleukin-6. PLoS Med 2009;6:e1000145.
30. Bogaard HJ1, Abe K, Vonk Noordegraaf A, Voelkel NF. The right ventricle under pressure: Cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 2009;135:794–804.
31. Venetz C, Labarère J, Jiménez D, Aujesky D. White blood cell count and mortality in patients with acute pulmonary embolism.
    Am J Hematol. 2013 Aug;88(8):677-81.
32. Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol 2010; 30: 1672-8.
33. Folsom AR, Lutsey PL, Astor BC, Cushman M. C-reactive protein and venous thromboembolism: a prospective investigation in the ARIC cohort. Thromb Haemost 2009; 102: 615-9.